Fadini GP, et al. - In this real-world study involving 473 patients initiating dapagliflozin and 336 patients initiating glucagon-like peptide-1 receptor agonists (GLP-1RA), researchers compared the simultaneous decreases in HbA1c, body weight, and systolic blood pressure after the beginning of dapagliflozin or GLP-1RA as second or more advanced line of therapy. For this investigation, they compared patients with type 2 diabetes (T2D) who initiated dapagliflozin or GLP-1RA (exenatide once weekly or liraglutide). According to findings, dapagliflozin initiation can be as effective in routine specialist care as initiating a GLP-1RA to achieve combined risk factor goals.